Chronic Oral Administration of CI-994: A Phase I Study

[1]  K. Walsh,et al.  Preclinical toxicity of a new oral anticancer drug, CI-994 (Acetyldinaline), in rats and dogs , 2004, Investigational New Drugs.

[2]  P. LoRusso,et al.  Preclinical antitumor activity of CI-994 , 2004, Investigational New Drugs.

[3]  L. Putten,et al.  Effectiveness of P-aminobenzyol-O-phenylenediamine (Goe 1734) against mouse, rat, and human tumour cells , 2004, Cancer Chemotherapy and Pharmacology.

[4]  P. Lorusso,et al.  Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline). , 1997, Investigational new drugs.

[5]  A. Kraker,et al.  Role of a small molecular weight phosphoprotein in the mechanism of action of CI‐994 (N‐acetyldinaline) , 1995, International journal of cancer.

[6]  M. Berger,et al.  New cytostatics--more activity and less toxicity. , 1990, Cancer treatment reviews.

[7]  C. R. Mehta,et al.  StatXact : a statistical package for exact non-parametric inference, Cytel Software Corporation, Cambridge, MA, USA , 1990 .

[8]  A. Hagenbeek,et al.  Dinaline: a new oral drug against leukemia? Preclinical studies in a relevant rat model for human acute myelocytic leukemia (BNML). , 1988, Leukemia.

[9]  B. Pool,et al.  Synthesis, toxicity, and therapeutic efficacy of 4-amino-N-(2'-aminophenyl)-benzamide: a new compound preferentially active in slowly growing tumors. , 1985, Cancer treatment reports.

[10]  F. Schabel,et al.  Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. , 1984, Cancer research.